Oppenheimer & Co. Inc. Invests $759,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

Oppenheimer & Co. Inc. bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 32,470 shares of the biopharmaceutical company's stock, valued at approximately $759,000.

A number of other institutional investors have also recently bought and sold shares of TGTX. NBC Securities Inc. lifted its holdings in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 485 shares during the period. Ashton Thomas Private Wealth LLC bought a new position in TG Therapeutics during the second quarter worth about $35,000. Blue Trust Inc. boosted its holdings in TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 849 shares in the last quarter. ORG Wealth Partners LLC bought a new stake in shares of TG Therapeutics in the 3rd quarter valued at approximately $53,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in shares of TG Therapeutics in the 1st quarter worth approximately $58,000. Institutional investors and hedge funds own 58.58% of the company's stock.

Insider Activity

In other news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now owns 100,195 shares of the company's stock, valued at $3,049,935.80. This represents a 4.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.50% of the stock is currently owned by insiders.

TG Therapeutics Price Performance

TGTX traded up $0.83 during midday trading on Wednesday, hitting $31.15. The company had a trading volume of 2,225,868 shares, compared to its average volume of 3,697,789. TG Therapeutics, Inc. has a twelve month low of $12.25 and a twelve month high of $36.50. The firm's 50-day simple moving average is $25.16 and its 200-day simple moving average is $21.42. The company has a market capitalization of $4.85 billion, a PE ratio of -311.47 and a beta of 2.19. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business's revenue for the quarter was down 49.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.73 EPS. Equities research analysts predict that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on TGTX shares. HC Wainwright boosted their price target on TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price target on the stock. Finally, B. Riley raised their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $37.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.